Bisphosphonates treatment in patients with osteoporosis;Behandlung der osteoporose mit bisphosphonaten

Therapeutische Umschau

Volumn 69, Issue 3, 2012, Pages 173-181

  Rizzoli, René ^a  

^a Abteilung für knochenerkrankungen   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ACUTE DISEASE; ARTICLE; DRUG EFFICACY; DRUG INDICATION; FRACTURE; GASTROINTESTINAL SYMPTOM; HIP FRACTURE; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; RISK REDUCTION; VERTEBRA FRACTURE;

BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; DIPHOSPHONATES; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; TRANSFORMING GROWTH FACTOR BETA;

EID: 84857981359     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930/a000270     Document Type: Article

References (35)

1. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348: 1535-41.
2. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett- Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998; 280: 2077-82.
3. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999; 282: 1344-52.
4. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000; 11: 83-91.
5. Chesnut IC, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004; 19: 1241-9.
6. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356: 1809-22.
7. Harris ST, Reginster JY, Harley C, Blumentals WA, Poston SA, Barr CE, et al. Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study. Bone. 2009; 44: 758-65.
8. Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int. 2007; 18: 25-34.
9. Ringe JD, Doherty JG. Absolute risk reduction in osteoporosis: assessing treatment efficacy by number needed to treat. Rheumatol Int. 2010; 30: 863-9.
10. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993; 8: 1137-48.
11. Smith-Bindman R, Cummings SR, Steiger P, Genant HK. A comparison of morphometric definitions of vertebral fracture. J Bone Miner Res. 1991; 6: 25-34.
12. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006; 296: 2927-38.
13. Thompson K, Rogers MJ. Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro. J Bone Miner Res. 2004; 19: 278-88.
14. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357: 1799-809.
15. Kennel KA, Drake MT. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc. 2009; 84: 632-7; quiz 8.
16. Bilezikian JP. Osteonecrosis of the jaw--do bisphosphonates pose a risk? N Engl J Med. 2006; 355: 2278-81.
17. Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone. 2008; 42: 841-7.
18. Armamento-Villareal R, Napoli N, Diemer K, Watkins M, Civitelli R, Teitelbaum S, et al. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int. 2009; 85: 37-44.
19. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005; 90: 1294-301.
20. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009; 360: 89-90.
21. Bolland MJ, Grey AB, Gamble GD, Reid IR. Effect of osteoporosis treatment on mortality: a metaanalysis. J Clin Endocrinol Metab. 2010; 95: 1174-81.
22. Rennert G, Pinchev M, Rennert HS. Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol. 2010; 28: 3577-81.
23. Chlebowski RT, Chen Z, Cauley JA, Anderson G, Rodabough RJ, Mc- Tiernan A, et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol. 2010; 28: 3582-90.
24. Singh H, Nugent Z, Demers A, Mahmud S, Bernstein C. Exposure to bisphosphonates and risk of colorectal cancer: A population-based nested case-control study. Cancer. 2011 [Epub ahead of print].
25. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006; 81: 1013-22.
26. Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, et al. Compliance with osteoporosis medications. Arch Intern Med. 2005; 165: 2414-9.
27. Sheehy O, Kindundu C, Barbeau M, LeLorier J. Adherence to weekly oral bisphosphonate therapy: cost of wasted drugs and fractures. Osteoporos Int. 2009; 20: 1583-94.
28. European Medicines Agency 2006. Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. CPMP/EWP/552/95 Rev. 2. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003405.pdf. Last accessed 27 October 2010.
29. International Osteoporosis Foundation 2009. About osteoporosis: prevention. Available at: http://www.iofbonehealth.org/patientspublic/about-osteoporosis/prevention.html. Last accessed 27 October 2010.
30. Novartis Pharma Stein AG 2009. Reclast (Zoledronic Acid) Injection Prescribing Information.
31. Roche Registration Limited 2009. Bonviva Summary of Product Characteristics.
32. Merck Sharp & Dohme Limited 2010. Fosamax Summary of Product Characteristics.
33. European Medicines Agency 2009 Assessment report for Fosavance. EMEA/CHMP/188952/2009. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000619/WC500024252.pdf. Last accessed 27 October 2010.
34. U.S. Food and Drug Administration 2009. Drug safety newsletter. Volume 2, Number 2. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/DrugSafetyNewsletter/UCM168579.pdf. Last accessed 27 October 2010.
35. Rizzoli R. Zoledronic acid for the treatment and prevention of primary and secondary osteoporosis. Ther Adv Musculoskel Dis 2010; 2: 3-16.